Aytu BioPharma, Inc. (AYTU)
USD 1.0
(-3.68%)
USD 1.0
(-3.68%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 | -2.86 USD | 44.03% |
| 2023 | -5.11 USD | 93.1% |
| 2022 | -74.01 USD | -6.34% |
| 2021 | -69.60 USD | -15.61% |
| 2020 | -60.20 USD | 95.03% |
| 2019 | -1210.28 USD | 60.46% |
| 2018 | -3061.23 USD | 98.42% |
| 2017 | -193.19 Thousand USD | 85.08% |
| 2016 | -1.29 Million USD | -134.69% |
| 2015 | -551.67 Thousand USD | 11.0% |
| 2014 | -619.85 Thousand USD | -8551.45% |
| 2013 | -7164.75 USD | 3.95% |
| 2012 | -7459.37 USD | 56.38% |
| 2011 | -17.1 Thousand USD | -70.24% |
| 2010 | -10.04 Thousand USD | 14.72% |
| 2009 | -11.77 Thousand USD | -3.01% |
| 2008 | -11.43 Thousand USD | 76.64% |
| 2007 | -48.95 Thousand USD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q3 | -0.52 USD | -1200.0% |
| 2024 Q1 | -1.48 USD | -150.85% |
| 2024 Q4 | -0.82 USD | -59.62% |
| 2024 Q2 | -0.04 USD | 97.3% |
| 2023 Q4 | -0.59 USD | 69.43% |
| 2023 Q3 | -1.93 USD | 10.23% |
| 2023 FY | - USD | 93.18% |
| 2023 Q1 | -0.28 USD | 96.87% |
| 2023 Q2 | -2.15 USD | -667.86% |
| 2022 Q3 | -35.90 USD | -310.76% |
| 2022 Q4 | -8.95 USD | 75.07% |
| 2022 FY | - USD | -7.67% |
| 2022 Q2 | -8.74 USD | 97.99% |
| 2022 Q1 | -435.20 USD | -2586.42% |
| 2021 Q1 | -7.00 USD | -25.0% |
| 2021 Q4 | -16.20 USD | 42.55% |
| 2021 Q2 | -14.40 USD | -105.71% |
| 2021 Q3 | -28.20 USD | -95.83% |
| 2021 FY | - USD | -325.23% |
| 2020 Q4 | -5.60 USD | 81.46% |
| 2020 FY | - USD | 98.65% |
| 2020 Q3 | -30.20 USD | -1158.33% |
| 2020 Q1 | -64.32 USD | 69.41% |
| 2020 Q2 | -2.40 USD | 96.27% |
| 2019 Q2 | -143.83 USD | 63.28% |
| 2019 Q1 | -391.69 USD | -743.06% |
| 2019 Q4 | -210.29 USD | -111.9% |
| 2019 FY | - USD | 60.46% |
| 2019 Q3 | -99.24 USD | 31.0% |
| 2018 Q1 | -4019.93 USD | 72.76% |
| 2018 FY | - USD | 98.42% |
| 2018 Q4 | 60.91 USD | 106.41% |
| 2018 Q3 | -950.97 USD | 73.38% |
| 2018 Q2 | -3572.64 USD | 11.13% |
| 2017 Q3 | -30.32 Thousand USD | 15.01% |
| 2017 Q2 | -35.68 Thousand USD | 60.73% |
| 2017 Q4 | -14.75 Thousand USD | 51.34% |
| 2017 FY | - USD | 85.08% |
| 2017 Q1 | -90.86 Thousand USD | 72.68% |
| 2016 Q3 | -316.26 Thousand USD | -32.87% |
| 2016 Q4 | -332.55 Thousand USD | -5.15% |
| 2016 Q1 | -162.58 Thousand USD | -5.6% |
| 2016 Q2 | -238.02 Thousand USD | -46.4% |
| 2016 FY | - USD | -134.69% |
| 2015 Q1 | -1244.00 USD | 5.31% |
| 2015 Q4 | -153.96 Thousand USD | 91.64% |
| 2015 Q3 | -1.84 Million USD | -105141.48% |
| 2015 Q2 | -1750.44 USD | -40.71% |
| 2015 FY | - USD | 11.0% |
| 2014 Q1 | -65.85 USD | 96.03% |
| 2014 Q2 | -2063.37 USD | -3033.44% |
| 2014 Q4 | -1313.78 USD | -1321610.26% |
| 2014 Q3 | -0.10 USD | 100.0% |
| 2014 FY | - USD | -8551.45% |
| 2013 Q2 | -2482.37 USD | -2108.12% |
| 2013 FY | - USD | 3.95% |
| 2013 Q4 | -1658.12 USD | 2.88% |
| 2013 Q3 | -1707.37 USD | 31.22% |
| 2013 Q1 | -112.42 USD | 92.47% |
| 2012 FY | - USD | 56.38% |
| 2012 Q4 | -1492.50 USD | -18.46% |
| 2012 Q3 | -1259.87 USD | 48.75% |
| 2012 Q2 | -2458.37 USD | -449.84% |
| 2012 Q1 | -447.11 USD | 84.89% |
| 2011 Q3 | -3833.57 USD | -29.84% |
| 2011 Q2 | -2952.50 USD | -2417.91% |
| 2011 Q4 | -2959.29 USD | 22.81% |
| 2011 Q1 | -117.26 USD | 95.28% |
| 2011 FY | - USD | -70.24% |
| 2010 FY | - USD | 14.72% |
| 2010 Q1 | -112.35 USD | 94.11% |
| 2010 Q2 | -3813.20 USD | -3294.04% |
| 2010 Q3 | -2446.40 USD | 35.84% |
| 2010 Q4 | -2483.50 USD | -1.52% |
| 2009 Q4 | -1906.60 USD | 40.03% |
| 2009 Q3 | -3179.00 USD | 28.5% |
| 2009 Q2 | -4446.00 USD | -3487.8% |
| 2009 Q1 | -123.92 USD | 96.54% |
| 2009 FY | - USD | -3.01% |
| 2008 Q4 | -3577.00 USD | -60.59% |
| 2008 Q3 | -2227.40 USD | 85.87% |
| 2008 Q2 | -15.75 Thousand USD | -13365.78% |
| 2008 Q1 | -117.03 USD | 99.18% |
| 2008 FY | - USD | 76.64% |
| 2007 Q4 | -14.25 Thousand USD | 7.94% |
| 2007 FY | - USD | 0.0% |
| 2007 Q3 | -15.48 Thousand USD | -106.21% |
| 2007 Q2 | -7510.00 USD | 0.0% |
| 2006 Q4 | -1905.00 USD | 0.0% |